References
1. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication ofHelicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-397.
2. Karim Z, Lyoumi S, Nicolas G, Deybach JC, Gouya L, Puy H. Porphyrias: a 2015 update. Clin Res Hepatol Gastroenterol 2015;39:412-425.
3. Spiritos Z, Salvador S, Mosquera D, Wilder J. Acute intermittent porphyria: current perspectives and case presentation. Ther Clin Risk Managt 2019;15:1443-1451.
4. Takata T, Kume K, Kokudo Y, et al. Acute intermittent porphyria presenting with posterior reversible encephalopathy syndrome, accompanied by prolonged vasoconstriction. Intern Med 2017;56:713-717.
5. Asaka M, Satoh K, Sugano K, et al. Guidelines in the management ofHelicobacter pylori infection in Japan. Helicobacter 2001;6:177-186.
6. Zhou S, Chan SY, Goh BC, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304.